Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - What happened at FDA? Replimune approval raises questions
- What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer - Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science
